Memorial Sloan Kettering, Atara Biotherapeutics deal
Atara exercised its option to license exclusive, worldwide rights to develop and commercialize three allogeneic T cell therapy programs from the center. The programs are EBV-CTL, which consists of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes and is in Phase II testing to treat EBV-positive lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation (HSCT); CMV-CTL, which consists of cytomegalovirus (CMV)-specific cytotoxic T lymphocytes and is in Phase II testing to treat CMV viremia or infection following allogeneic HSCT; and WT1-CTL, which consists of Wilms tumor 1 ( WT1)-specific cytotoxic T lymphocytes and is in Phase I testing to treat acute myelogenous leukemia (AML) and multiple myeloma (MM). Earlier this year, FDA granted EBV-CTL breakthrough therapy designation to treat rituximab-refractory EBV-associated lymphoproliferative disease. ...